The progress and perspectives of CAR-T cell therapy |
| |
Authors: | Yan Peng Zhenqing Feng |
| |
Institution: | 1.National Health Commission Key Lab. of Antibody Techniques, Nanjing Medical University, Nanjing, Jiangsu 211166, China2.Department of Pathology, Nanjing Medical University, Nanjing, Jiangsu 211166, China |
| |
Abstract: | CAR-T cell therapy has already achieved world-renowned clinical effects in the treatment of hematological malignancies. Due to the tumor heterogeneity, immunosuppressive microenvironment, and other factors, CAR-T cell therapy has still not shown obvious clinical efficacy in clinical treatment of solid tumors. However, great progress has been made in the preparation of CAR-T cells in recent years, including T cells redirected for universal cytokine mediated killing, universal CAR -T cells, non-viral vector CAR-T cells, SynNotch technology, SUPRA CAR technology, regulated CAR-T cells, and bi-specific CAR-T cells, etc. Future research and development of CAR-T cell therapy will be focused on these following aspects: the combined application of CAR-T cells with different targets, known as "Cocktail CAR-T cells", is expected to increase efficiency toward solid tumors; based on systemic biology/synthetic biology theories, CAR-T cells are likely to be transformed to robot or intelligent system by introducing sensors, logic gates, and logic circuits. This article mainly comments on research progress and perspectives on CAR-T cell therapy in solid tumor treatment. |
| |
Keywords: | CAR-T cell solid tumor cell therapy |
|
| 点击此处可从《Blood and Genomics》浏览原始摘要信息 |
| 点击此处可从《Blood and Genomics》下载免费的PDF全文 |
|